|
시장보고서
상품코드
2032382
초붕괴제 시장 보고서 : 제품별, 유형별, 제형별, 치료 영역별, 지역별(2026-2034년)Superdisintegrants Market Report by Product, Type, Dosage Form, Therapeutic Areas, and Region 2026-2034 |
||||||
세계의 초붕괴제 시장 규모는 2025년에 4억 6,950만 달러에 이르렀습니다. 향후 IMARC Group은 2026-2034년 CAGR은 5.73%를 나타내 2034년까지 시장 규모가 7억 8,720만 달러에 이를 것으로 예측했습니다.
초붕괴제는 정제나 캡슐을 더 작은 입자로 붕괴, 분해시키기 위해 제제에 첨가하는 개량형 붕괴제를 말합니다. 이는 체내 약물의 흡수와 유효성분(API)의 용해도를 높여 경구용 고형제제의 붕괴 시간을 단축하고 약효를 높이는 데 도움이 됩니다. 이들은 고형 제제에서 저농도로 사용되며, 일반적으로 1회 투여량 총 중량 대비 1-10%의 비율로 배합됩니다. 현재 합성 및 천연 변형이 가능하며 심혈관 질환, 감염성 질환, 혈액 질환, 신경 질환, 소화기 질환, 염증성 질환 등 다양한 치료 영역에서 사용되고 있습니다.
초붕괴제 시장 동향 :
현재, 고체 제제는 제약 산업에서 큰 비중을 차지하고 있습니다. 이 외에도 다양한 노화 및 만성 질환을 앓고 있는 사람들 증가는 시장 성장을 가속하는 주요 요인 중 하나입니다. 또한, 항정신병제, 항우울제, 편두통 치료제, 진정제를 위한 구강붕해정제(ODT) 제조에 초붕괴제가 널리 사용되고 있다는 점은 업계 투자자들에게 매력적인 성장 기회를 제공합니다. 이 외에도 높은 적합성, 향상된 생체 이용률, 효율적인 압축성 등의 특성은 전 세계적으로 초붕괴제에 대한 수요를 촉진하고 있습니다. 또한, 주요 기업들은 시장에서의 경쟁 우위를 유지하기 위해 제품 개발 및 새로운 제형 혁신에 많은 투자를 하고 있습니다. 또한, 엄격한 규제로 인해 제약업계는 보다 안전한 대체품의 사용을 장려하고 있으며, 이는 전 세계적으로 천연 유래 초붕괴제의 보급을 촉진하고 있습니다. 또한, 신경질환의 부담 증가와 더불어 COVID19 확산에 따른 원격의료의 보급이 맞물려 시장 성장을 견인할 것으로 예측됩니다.
본 보고서에서 답변을 얻을 수 있는 주요 질문
- 지금까지의 세계 초붕괴제 시장 동향은 어떠했으며, 향후 몇 년 동안 어떻게 변화할 것인가?
- 코로나19는 세계 초붕괴제 시장에 어떤 영향을 미쳤는가?
- 주요 지역 시장은?
- 제품별로 보면, 시장 내역은?
- 시장 유형별 시장 분석은?
- 제형별 시장 현황은?
- 치료 영역별 시장 현황은?
- 이 산업의 가치사슬에서 각 단계는 어떤 역할을 하는가?
- 이 산업의 주요 촉진요인과 과제는?
- 세계 초붕괴제 시장의 구조는 무엇이며, 주요 기업은?
- 업계 내 경쟁은 어느 정도 치열합니까?
목차
제1장 서문
제2장 조사 범위와 조사 방법
제3장 주요 요약
제4장 서론
제5장 세계의 초붕괴제 시장
제6장 시장 분석 : 제품별
제7장 시장 분석 : 유형별
제8장 시장 분석 : 제형별
제9장 시장 분석 : 치료 영역별
제10장 시장 분석 : 지역별
제11장 SWOT 분석
제12장 밸류체인 분석
제13장 Porter's Five Forces 분석
제14장 가격 분석
제15장 경쟁 구도
KTH 26.05.15The global superdisintegrants market size reached USD 469.5 Million in 2025. Looking forward, IMARC Group expects the market to reach USD 787.2 Million by 2034, exhibiting a growth rate (CAGR) of 5.73% during 2026-2034.
Superdisintegrants are modified disintegrants added in drug formulations to facilitate the breakup or disintegration of tablets or capsules into smaller particles. They assist in increasing the absorption of the drug and the solubility of active pharmaceutical ingredients (APIs) in the body, thereby reducing the disintegration time or oral solid dosage forms and enhancing their efficiency. They are utilized at a low level in the solid dosage form, generally 1- 10% by weight relative to the total weight of the dosage unit. Presently, they are available in synthetic and natural variants and used in many therapeutic areas, such as cardiovascular, infectious, hematological, neurological, gastrointestinal diseases, and inflammatory diseases.
SUPERDISINTEGRANTS MARKET TRENDS:
Solid dosage medicines currently hold a significant share in the pharmaceutical industry. This, coupled with the rising number of people suffering from various age-related and chronic diseases, represents one of the key factors strengthening the growth of the market. Moreover, the extensive usage of superdisintegrants in the production of orally disintegrating tablets (ODTs) for antipsychotics, antidepressants, antimigraine, and sedatives is offering lucrative growth opportunities to industry investors. Apart from this, features like high compatibility, improved bioavailability, and efficient compressibility are catalyzing the demand for superdisintegrants worldwide. Additionally, leading players are considerably investing in product development and innovation of novel formulations to retain a competitive edge in the market. Besides this, stringent regulations are propelling the use of safer alternatives in the pharmaceutical industry, which is assisting in the wider acceptance of natural superdisintegrants around the world. Furthermore, the growing burden of neurological disorders, in confluence with the increasing popularity of telemedicine on account of the coronavirus disease (COVID-19) outbreak, is anticipated to impel the market growth.
KEY MARKET SEGMENTATION:
Breakup by Product:
- Croscarmellose Sodium
- Crospovidone
- Sodium Starch Glycolate
- Ion Exchange Resin
- Modified Cellulose
- Others
Breakup by Type:
- Natural Superdisintegrant
- Synthetic Superdisintegrant
- Others
Breakup by Dosage Form:
- Tablets and Capsules
- Mouth-Dissolving Films
Breakup by Therapeutic Areas:
- Gastrointestinal
- Cardiovascular
- Neurology
- Oncology
- Hematology
- Others
Breakup by Region:
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
COMPETITIVE LANDSCAPE:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Asahi Kasei Corporation, Ashland Global Specialty Chemicals Inc., Avantor Inc., BASF SE, Corel Pharma Chem, DFE Pharma GmbH & Co. KG, DuPont de Nemours Inc., JRS Pharma GmbH & Co. KG, Merck KGaA, Nippon Soda Co. Ltd., Roquette Freres and Sigachi Industries Limited.
KEY QUESTIONS ANSWERED IN THIS REPORT
- How has the global superdisintegrants market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the global superdisintegrants market?
- What are the key regional markets?
- What is the breakup of the market based on the product?
- What is the breakup of the market based on the type?
- What is the breakup of the market based on the dosage form?
- What is the breakup of the market based on the therapeutic areas?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global superdisintegrants market and who are the key players?
- What is the degree of competition in the industry?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Superdisintegrants Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Product
- 6.1 Croscarmellose Sodium
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Crospovidone
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
- 6.3 Sodium Starch Glycolate
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
- 6.4 Ion Exchange Resin
- 6.4.1 Market Trends
- 6.4.2 Market Forecast
- 6.5 Modified Cellulose
- 6.5.1 Market Trends
- 6.5.2 Market Forecast
- 6.6 Others
- 6.6.1 Market Trends
- 6.6.2 Market Forecast
7 Market Breakup by Type
- 7.1 Natural Superdisintegrant
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Synthetic Superdisintegrant
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 Others
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
8 Market Breakup by Dosage Form
- 8.1 Tablets and Capsules
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Mouth-Dissolving Films
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
9 Market Breakup by Therapeutic Areas
- 9.1 Gastrointestinal
- 9.1.1 Market Trends
- 9.1.2 Market Forecast
- 9.2 Cardiovascular
- 9.2.1 Market Trends
- 9.2.2 Market Forecast
- 9.3 Neurology
- 9.3.1 Market Trends
- 9.3.2 Market Forecast
- 9.4 Oncology
- 9.4.1 Market Trends
- 9.4.2 Market Forecast
- 9.5 Hematology
- 9.5.1 Market Trends
- 9.5.2 Market Forecast
- 9.6 Others
- 9.6.1 Market Trends
- 9.6.2 Market Forecast
10 Market Breakup by Region
- 10.1 North America
- 10.1.1 United States
- 10.1.1.1 Market Trends
- 10.1.1.2 Market Forecast
- 10.1.2 Canada
- 10.1.2.1 Market Trends
- 10.1.2.2 Market Forecast
- 10.1.1 United States
- 10.2 Asia-Pacific
- 10.2.1 China
- 10.2.1.1 Market Trends
- 10.2.1.2 Market Forecast
- 10.2.2 Japan
- 10.2.2.1 Market Trends
- 10.2.2.2 Market Forecast
- 10.2.3 India
- 10.2.3.1 Market Trends
- 10.2.3.2 Market Forecast
- 10.2.4 South Korea
- 10.2.4.1 Market Trends
- 10.2.4.2 Market Forecast
- 10.2.5 Australia
- 10.2.5.1 Market Trends
- 10.2.5.2 Market Forecast
- 10.2.6 Indonesia
- 10.2.6.1 Market Trends
- 10.2.6.2 Market Forecast
- 10.2.7 Others
- 10.2.7.1 Market Trends
- 10.2.7.2 Market Forecast
- 10.2.1 China
- 10.3 Europe
- 10.3.1 Germany
- 10.3.1.1 Market Trends
- 10.3.1.2 Market Forecast
- 10.3.2 France
- 10.3.2.1 Market Trends
- 10.3.2.2 Market Forecast
- 10.3.3 United Kingdom
- 10.3.3.1 Market Trends
- 10.3.3.2 Market Forecast
- 10.3.4 Italy
- 10.3.4.1 Market Trends
- 10.3.4.2 Market Forecast
- 10.3.5 Spain
- 10.3.5.1 Market Trends
- 10.3.5.2 Market Forecast
- 10.3.6 Russia
- 10.3.6.1 Market Trends
- 10.3.6.2 Market Forecast
- 10.3.7 Others
- 10.3.7.1 Market Trends
- 10.3.7.2 Market Forecast
- 10.3.1 Germany
- 10.4 Latin America
- 10.4.1 Brazil
- 10.4.1.1 Market Trends
- 10.4.1.2 Market Forecast
- 10.4.2 Mexico
- 10.4.2.1 Market Trends
- 10.4.2.2 Market Forecast
- 10.4.3 Others
- 10.4.3.1 Market Trends
- 10.4.3.2 Market Forecast
- 10.4.1 Brazil
- 10.5 Middle East and Africa
- 10.5.1 Market Trends
- 10.5.2 Market Breakup by Country
- 10.5.3 Market Forecast
11 SWOT Analysis
- 11.1 Overview
- 11.2 Strengths
- 11.3 Weaknesses
- 11.4 Opportunities
- 11.5 Threats
12 Value Chain Analysis
13 Porters Five Forces Analysis
- 13.1 Overview
- 13.2 Bargaining Power of Buyers
- 13.3 Bargaining Power of Suppliers
- 13.4 Degree of Competition
- 13.5 Threat of New Entrants
- 13.6 Threat of Substitutes
14 Price Analysis
15 Competitive Landscape
- 15.1 Market Structure
- 15.2 Key Players
- 15.3 Profiles of Key Players
- 15.3.1 Asahi Kasei Corporation
- 15.3.1.1 Company Overview
- 15.3.1.2 Product Portfolio
- 15.3.1.3 Financials
- 15.3.1.4 SWOT Analysis
- 15.3.2 Ashland Global Specialty Chemicals Inc.
- 15.3.2.1 Company Overview
- 15.3.2.2 Product Portfolio
- 15.3.2.3 Financials
- 15.3.2.4 SWOT Analysis
- 15.3.3 Avantor Inc.
- 15.3.3.1 Company Overview
- 15.3.3.2 Product Portfolio
- 15.3.3.3 Financials
- 15.3.4 BASF SE
- 15.3.4.1 Company Overview
- 15.3.4.2 Product Portfolio
- 15.3.4.3 Financials
- 15.3.4.4 SWOT Analysis
- 15.3.5 Corel Pharma Chem
- 15.3.5.1 Company Overview
- 15.3.5.2 Product Portfolio
- 15.3.6 DFE Pharma GmbH & Co. KG
- 15.3.6.1 Company Overview
- 15.3.6.2 Product Portfolio
- 15.3.7 DuPont de Nemours Inc.
- 15.3.7.1 Company Overview
- 15.3.7.2 Product Portfolio
- 15.3.7.3 Financials
- 15.3.7.4 SWOT Analysis
- 15.3.8 JRS Pharma GmbH & Co. KG
- 15.3.8.1 Company Overview
- 15.3.8.2 Product Portfolio
- 15.3.9 Merck KGaA
- 15.3.9.1 Company Overview
- 15.3.9.2 Product Portfolio
- 15.3.9.3 Financials
- 15.3.9.4 SWOT Analysis
- 15.3.10 Nippon Soda Co. Ltd.
- 15.3.10.1 Company Overview
- 15.3.10.2 Product Portfolio
- 15.3.10.3 Financials
- 15.3.10.4 SWOT Analysis
- 15.3.11 Roquette Freres
- 15.3.11.1 Company Overview
- 15.3.11.2 Product Portfolio
- 15.3.11.3 SWOT Analysis
- 15.3.12 Sigachi Industries Limited
- 15.3.12.1 Company Overview
- 15.3.12.2 Product Portfolio
- 15.3.1 Asahi Kasei Corporation
